August 2026 FDA Recall Prasugrel by Mylan Pharmaceuticals Inc
D-0839-2026 - Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

This Class II drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc on August 17, 2026 for the product Prasugrel. The FDA reported the reason for recall as failed dissolution specifications; product failed to meet 18-month stability testing acceptance criteria. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0839-2026

Reason for Recall
Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria
Initiated
08-17-2026
Reported
09-09-2026
Quantity
47,662 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Mylan Pharmaceuticals Inc
Nationwide within the U.S
Prasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 0378-5186-93.

Batch or Lot Expiration Information

Lot# : 3225272, Exp. September 30, 2026

Affected Packages Involved in this Recall